维普中文期刊产品整合服务
179篇 您的检索式:作者名="Kurien"
    题名 作者 年代 出处 被引量
1Attributable cost of a nosocomial infection in the intensive care unit: A prospective cohort study显示文摘AIM To study the impact of hospital-acquired infections(HAIs) on cost and outcome from intensive care units(ICU) in India. METHODS Adult patients(> 18 years) admitted over 1-year, to a 24-bed medical critical care unit in India, were enrolled prospectively. Treatment cost and outcome data were collected. This cost data was merged with HAI data collected prospectively by the Hospital Infection Control Committee. Only infections occurring during ICU stay were included. The impact of HAI on treatment cost and mortality was assessed. RESULTS The mean(± SD) age of the cohort(n = 499) was42.3 ± 16.5 years. Acute physiology and chronic health evaluation-Ⅱ score was 13.9(95%CI: 13.3-14.5); 86% were ventilated. ICU and hospital length of stay were 7.8 ± 5.5 and 13.9 ± 10 d respectively. Hospital mortality was 27.9%. During ICU stay, 76(15.3%) patients developed an infection(ventilator-associated pneumonia 50; bloodstream infection 35; urinary tract infections 3), translating to 19.7 infections/1000 ICU days. When compared with those who did not develop an infection, an infection occurring during ICU stay was associated with significantly higher treatment cost [median(inter-quartile range, IQR) INR 92893(USD 1523)(IQR 57168-140286) vs INR 180469(USD 2958)(IQR 140030-237525); P < 0.001 and longer duration of ICU(6.7 ± 4.5 d vs 13.4 ± 7.0 d; P < 0.01) and hospital stay(12.4 ± 8.2 d vs 21.8 ± 13.9 d; P < 0.001)]. However ICU acquired infections did not impact hospital mortality(31.6% vs 27.2%; P = 0.49).CONCLUSION An infection acquired during ICU stay was associated with doubling of treatment cost and prolonged hospitalization but did not significantly increase mortality.Binila Chacko Kurien Thomas Thambu David Hema Paul Lakshmanan Jeyaseelan John Victor Peter 2017World Journal of Critical Care Medicine2017,6,1:11
2Monocyte chemoattractant protein-1, transforming growth factor-β1, nerve growth factor, resistin and hyaluronic acid as serum markers:comparison between recurrent acute and chronic pancreatitis显示文摘BACKGROUND: Diagnostic parameters that can predict the presence of chronic pancreatitis(CP) in patients with recurrent pain due to pancreatitis would help to direct appropriate therapy. This study aimed to compare the serum levels of monocyte chemoattractant protein-1(MCP-1), transforming growth factor-β1(TGF-β1), nerve growth factor(NGF), resistin and hyaluronic acid(HA) in patients with recurrent acute pancreatitis(RAP) and CP to assess their ability to differentiate the two conditions.METHODS: Levels of serum markers assessed by enzymelinked immunosorbent assay(ELISA) were prospectively compared in consecutive patients with RAP, CP and in controls and stepwise discriminant analysis was performed to identify the markers differentiating RAP from CP.RESULTS: One hundred and thirteen consecutive patients(RAP=32, CP=81) and 78 healthy controls were prospectively enrolled. The mean(SD) age of the patients was 32.0(14.0)years; 89(78.8%) were male. All markers were significantly higher in CP patients than in the controls(P<0.001); MCP-1NGF and HA were significantly higher in RAP patients than in the controls(P<0.001). Stepwise discriminant analysis showed significant difference(P=0.002) between RAP and CP for resistin with an accuracy of 61.9%, discriminant scores of ≤-0.479 and ≥0.189 indicating RAP and CP, respectively. The other markers had no differential value between RAP and CP.CONCLUSION: Serum resistin is a promising marker to differentiate between RAP and CP and needs validation in future studies, especially in those with early CP.M Ganesh Kamath C Ganesh Pai Asha Kamath Annamma Kurien 2016Hepatobiliary & Pancreatic Diseases International2016,15,2:7
3Continuing episodes of pain in recurrent acute pancreatitis: Prospective follow up on a standardised protocol with drugs and pancreatic endotherapy显示文摘AIM To assess the outcomes of drug therapy(DT)followed by pancreatic endotherapy for continuing painful episodes in recurrent acute pancreatitis.METHODS DT comprised of pancreatic enzymes and antioxidants failing which,endotherapy(ET;pancreatic sphincterotomy and stent placement)was done.The frequency of pain,its visual analogue score(VAS),quality of life(Qo L),serum C peptide and faecal elastase were compared between baseline and after 1 year of follow up in all patients and in the two subgroups on DT and ET.Response was defined as at least 50%reduction in the severity of pain to below a score of 5.RESULTS Of the thirty nine patients analysed,21(53.9%)responded to DT and 18(46.1%)underwent ET.The VAS for pain(7.0±2.0 vs 1.3±2.5,P<0.001)and the number of days with pain per month decreased[1.0(1.0,2.0)vs 1.0(0.0,1.0),P<0.001],and the Qo L scores[55.0(44.0,66.0)vs 38.0(32.00,51.00),P<0.01]improved significantly during follow up.Similar significant improvements were seen in patients in the subgroups of DT and ET except for Qo L in ET.The serum C-peptide(P=0.001)and FE(P<0.001)levels improved significantly in the entire group and in the two subgroups of patients except for the C peptide levels in patients on DT.CONCLUSION A standardised protocol of DT,followed by ET decreased the intensity and frequency of pain in recurrent acute pancreatitis,enhanced Qo L and improved pancreatic function.C Ganesh Pai M Ganesh Kamath Mamatha V Shetty Annamma Kurien 2017World Journal of Gastroenterology2017,23,19:2
4Prolidase deficiency and the biochemical assays used in its diagnosis显示文摘Kurien BT Patel NC Porter AC 2006Anal Biochem2006,349,2:1
5Lipid peroxidation in systemic lupus erythematosus显示文摘]Kurien BT Scofield RH 2006Indian J Exp Biol2006,44,5:1
6Oxidatively modified autoantigens in autoimmune diseases显示文摘Kurien BT Hensley K Bachmann M 0,,04:1
7Chronic andenoid hypertrophy in children-Is steroid nasal spray beneficial显示文摘Anjali Lepcha Mary Kurien Anand Job 2002Indian Journal of Otolar Ngology and Head and Neck Surgery2002,54,4:1
8Colonialism and ethnogenesis: A study of Kerala, India显示文摘Prema Kurien 1994Theory and Society1994,,3:1
9Bioethanol production from rice straw: An overview显示文摘Binod P Sindhu R Singhania RR Vikram S Devi L Nagalakshmi S Kurien N Sukumaran RK Pandey A 2010Bioresource Technology2010,101,13:1
10A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis 显示文摘Rao GG Kurien A Gossett D 2006Gynecol Oncol2006,101,2:1
11Association of neutropenia in systemic lupus erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen显示文摘KURIEN B T NEWLAND J PACZKOWSKI C 2000Clin Exp Immunol2000,120,1:1
12Autoantibody determination in the diagnosis of systemic lupus erythematosus显示文摘Kurien BT Scefield RH 2006Stand J Immunol2006,9,3:1
13Serum-free-fatty-acids and arrhythmias after acute myocardial infarction显示文摘Oliver MF Kurien VA 1969Lancet1969,2,7629:1
14Hypertention secondary to progressive vascular Neurofibromatosis 显示文摘Kurien A John PR Milford DV 1997Arch Dis Child1997,76,5:1
15Inhibition of p300 and nuclear factor-kappaB by curcumin and its role in diabetic nephropathy显示文摘Kurien B T 2009Nutrition2009,25,9:1
16Complete mucostatic impression: A new attempt显示文摘Bindhoo YA Thirumurthy VR Kurien A 2012J Pro- sthodont2012,21,3:1
17Bioethanol production from rice straw: An overview显示文摘Parameswaran Binod Raveendran Sindhu Reeta Rani Singhania Surender Vikram Lalitha Devi Satya Nagalakshmi Noble Kurien Rajeev K. Sukumaran Ashok Pandey 2009Bioresource Technology2009,,13:1
18Immunization with 60-kD Ro peptide produces different stages of preclinical autoimmunity in a Sj(o)gren's syndrome model among multiple strains of inbred mice显示文摘Kurien BT Dsouza A Igoe A 2013Clin Exp Immunol2013,173,:1
19Percutaneous renal access training:content validation comparison between a live porcine and a virtual reality(VR)simulation model显示文摘Mishra S Kurien S Ganpule A 2010106(11):1753-17562010,106,11:1
20Allergic rhinitis and associated comorbidities:prevalence in oman with knowledge gaps in literature显示文摘Al-Abri R Bharghava D Kurien M 2014Oman Med J2014,29,6:1
返回顶部 每页显示:
共9页 首页 上一页 第1页 下一页 末页 /9 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费